FGF2 and soft tissue sarcoma: PTX3 has been described as a potent FGF2 inhibitor (14, 18, 19) and has been reported to be down-modulated in different types of cancer, including soft tissue sarcomas (21, 22) in which its absence exerts pro-tumor effects (13, 21).